Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.
ASLAN Pharmaceuticals Ltd Adr has received a notification from Nasdaq for not meeting the Stockholders’ Equity Requirement, with a deficit of $13.3 million, and must now submit a compliance plan by June 3, 2024. The company’s listing on Nasdaq remains active during this grace period, as they work to resolve the shortfall. ASLAN Pharmaceuticals is actively developing innovative treatments in immunology, including a potential first-in-class antibody for atopic dermatitis and an oral inhibitor for alopecia areata, with key clinical trial readouts expected.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.